Hypothesis:Anti-[18F]FACBC PET-CT will adequately detect local and extraprostatic
recurrence, and lead to better characterization of disease status in restaging patients.
This is a study that will test a compound (chemical substance) that has a small amount of
radioactivity attached to it. This substance has a natural tendency to go to prostate
tissue. The substance is called FACBC and it is given in the form of an injection into
a vein. After the substance reaches the prostate, scans called PET or Positron Emission
Tomography, are done. This is similar to having CAT scans or x-rays. Usually a compound
called FDG is used for PET scans but this substance is eliminated by the kidneys and
cannot reach the prostate. This substance called FACBC is not eliminated by the kidneys
and may allow tumors in the prostate to be seen better. It is sometimes difficult to tell
if a growth on the prostate is cancer with scans or x-rays that are usually done.
This study will look at how the FACBC goes into the prostate tissue and determine its
ability to detect recurrent prostate cancer.
STUDY NOW CLOSED for recruitment
- Patients must be 18 years of age or older.
- Patients will have been originally diagnosed with localized (Stage T1c, T2, or T3 )
prostate carcinoma and have undergone what was considered definitive therapy for
- In the case of brachytherapy, cryotherapy, or external beam radiation, treatment will
have occurred at least 2 years in the past to eliminate patients with so-called "PSA
- Patient will have suspicion of recurrent prostate carcinoma as defined by: ASTRO
criteria of three consecutive rises of PSA or earlier if clinically appropriate,
and/or nadir + 2.0 after radiotherapy, and/or greater than 0.3 after prostatectomy.
- Ability to lie still for PET scanning
- Patients must be able to provide written informed consent.
- Age less than 18.
- Greater than T3 disease in past
- Prior prostatectomy or 2 years since brachytherapy, cryotherapy, or external beam
- Does not meet above criteria of suspicious PSA elevation
- Inability to lie still for PET scanning
- Cannot provide written informed consent.
- Bone scan findings characteristic for metastatic prostate carcinoma
- Less than 2 months since any prior prostate biopsy (to decrease false positive uptake